Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06683716

SmartGlass-Guided ERCP with Cannulation of Native Papilla 1.0

The aim of this prospective randomized study is to evaluate whether telemedical assistance via SmartGlasses is equivalent to physical presence in teaching Endoscopic Retrograde Cholangiopancreaticography (ERCP) in terms of examination success and safety. Endoscopic papilla cannulation is a key skill for successful ERCP and therefore a measurable primary endpoint of the study. This can be measured as the time (in seconds/minutes) between stable visualization of the papilla and successful endoscopic cannulation of the target structure (bile duct or pancreatic duct).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Helios Kliniken Schwerin

Schwerin, Mecklenburg-Vorpommern, 19055, Germany

Location contact

Daniel Schmitz, Dr.med.

CONTACT

Jens Nürnberger, Prof. Dr. med.

CONTACT

[email protected]

+49-385-520-2050

Jörg-Peter Ritz (Medical director of the whole hospital), Prof. Dr. med.

CONTACT

[email protected]

+49-385-520-2050

Stefan Prax, Dr.med.

CONTACT

About this study

In sparsely populated regions of a country and where there is a lack of experienced specialists, it may not always be possible to have an experienced ERCP examiner present during an examination. Therefore, telemedical examination assistance via a connection to data glasses worn by the examiner is a possible option to replace the physical presence of an instructor or experienced ERCP examiner.

The aim of this prospective randomized study is to evaluate whether telemedical assistance via smart glasses is equivalent to physical presence in terms of examination success and safety. Endoscopic papilla cannulation is a key skill for successful ERCP and therefore a measurable primary endpoint of the study. This can be measured as the time (in seconds/minutes) between stable visualization of the papilla and successful endoscopic cannulation of the target structure (bile duct or pancreatic duct).

In addition to other efficacy endpoints, adverse events, which are expected to be rare, will be documented at 48-hour intervals and calculated as a rate. Telemedical 'live' support of an ERCP via data glasses has not yet been demonstrated or tested in a trial. To ensure the safety of the examination under these circumstances, the training examiner is present in the neighbouring room and can physically assist or take over the examination at any time if necessary.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients aged ≥ 18 years without previous papillotomy Exclusion criteria
  • Cannulation of the minor papilla necessary
  • Significant comorbidity
  • Haemodynamic instability
  • Pregnant women
  • Refusal or inability to give written informed consent for the study
  • Instructor had to perform the examination himself/herself

Treatment and study plan

Training in presence of the instructor

Other

The instructor gives the trainee instructions for the examination while he/she is present in the examination room.

Telemedically training by an instructor

Other

The trainer gives instructions to the trainee through a telemedical connection to the examiner using SmartGlasses

Primary outcomes

  1. Papilla cannulation time

    Time frame: During the intervention: from the stable visualisation of the papilla until the successful cannulation of the papilla, assessed up to 60 minutes

    Time to cannulate the native papilla during ERCP

Secondary outcomes

  1. Adverse events during and after ERCP

    Time frame: Time interval between insertion of the endoscope through the mouth up to 48 hours after ERCP

    All adverse events that occur during ERCP and after ERCP: number (n)

Study contacts

Contact information is provided by the study sponsor or research team.

Daniel Schmitz, Dr. med.

CONTACT

[email protected]

+49-385-520-2601

Martin Kliment, Dr.med.

CONTACT

[email protected]

+49-385-520-2601

Sponsors and collaborators

Lead sponsor

Helios Kliniken Schwerin

Other

Registry information

Official study title

Remote Assistance Via Smart Glasses Compared to In-person Assistance for Cannulation of the Native Papilla During Endoscopic Retrograde Cholangiopancreatography

Acronym: EmeRald

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Nov 12, 2024
Registry last updated
Nov 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.